Research Presentations by Corporate Affiliate Visiting Fellows (Session 2)

Research Presentations by Corporate Affiliate Visiting Fellows (Session 2)

Wednesday, May 27, 2009
12:00 PM - 2:00 PM
(Pacific)
Philippines Conference Room

In this session of the Shorenstein APARC Corporate Affiliate Visiting Fellows Research Presentations, the following will be presented:

Hiroyuki Koyano, "The Strategy for Accerlation of Patent Examination - Focusing on Human Resource Management"

The number of patent application filings has increased across the world as a result of the globalization of the world economy. In addition, technology has become more complex and the demands for a quality patent has grown. Working against this trend, the period of patent examination has become longer, so patent offices have adopted plans to remedy the situation and accelerate patent examination. Hiroyuki Koyano attempts to compare the United States Patent and Trademark Office’s (USPTO) plans with those of JPO’s and analyze the problems focusing mainly on human resource management.

Mitsue Kurihara, "The Recent M&A Boom in Japan"

Mergers and Acquisitons in Japan have been booming since the late 1990s. What initially started as a method for industrial rehabilitation, today, M&A is put to use by many companies as part of their corporate strategy. Utilizing her experiences as an advisor for M&A, Kurihara researches the remarkable trend in the boom of Japanese M&A over the last ten years, as well as the future of Japanese M&A market in terms of where it should be headed.

Bhavna Sharma, “Polymorphisms in Breast Cancer Mutation Carriers: Comparative Studies in Caucasian and Hong Kong Population”

Breast cancer rates differ significantly in Asia compared to the United States and other western countries.  Lifestyle and genetic differences between these populations are probably causes of this variation.  Sharma presents findings from her study that hypothesized that the genetic breast cancer risk factors that differ between BRCA1/2 mutation carriers in Asia and the U.S. may result in a different magnitude of breast cancer risk among Asians versus Caucasians who carry BRCA1/2 mutations.